Now Playing
Opinion|Videos|April 12, 2024
Overview of Tumor agnostic Treatment: Considerations for NGS Testing in Solid Tumors
Experts discuss the importance of NGS testing for identifying actionable alterations like RET fusions in solid tumors and when to consider testing.
Advertisement
Episodes in this series
Advertisement
Related to this article
Estelamari Rodriguez, MD, MPH, discusses the rationale, design, and practice implications of the phase 3 RELATIVITY-1093 trial in nonsquamous NSCLC.
Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.
The third BLA submission for tabelecleucel follows 2 CRLs and includes updated ALLELE data with additional patients and longer follow-up.
A New England Journal of Medicine report describes complete hepatoblastoma regression in a 3-year-old treated with a novel immunotherapy.
Plinabulin plus docetaxel received fast track designation for pretreated nonsquamous NSCLC without actionable genomic alterations.
FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy
Denosumab-adet (Degevma) is FDA approved as an Xgeva biosimilar for SRE prevention in myeloma and bone metastases, giant cell tumor of bone, and HCM.
Faculty convened at an OncLive Scientific Interchange and Workshop to discuss individualized treatment and strategic sequencing in HER2-mutated NSCLC.
Researchers at Wake Forest University School of Medicine identified a protein that may help breast cancer spread to the brain and evade immune defenses.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Approval Signals a New Era for RAS-Targeted Therapy in Pancreatic Cancer
2
FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy
3
CNS Control and Daily Tolerability Guide Treatment Sequencing in HER2-Mutated NSCLC
4
Dr Pelster on the MAPKeeper 301 Trial Evaluating Atebimetinib in First-Line Metastatic Pancreatic Cancer
5